Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SER-155 for First-Line Treatment of Immunotherapy-Related Enterocolitis
NCT06801067Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SER-155 in enterocolitis, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Proportion of participants with treatment-related adverse events of special interest at 1 year and Proportion of patients with treatment-related adverse events at 1 year. Started Jan 2025; status: recruiting.
02
Drugs
SER-155
03
Conditions
enterocolitis
Beyond the preview
Go deeper on NCT06801067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801067.